BIO Share Price

Open 27.11 Change Price %
High 27.44 1 Day -0.02 -0.07
Low 27.11 1 Week 0.07 0.26
Close 27.25 1 Month -0.73 -2.61
Volume 9244 1 Year 10.11 58.98
52 Week High 28.60
52 Week Low 15.44
BIO Important Levels
Resistance 2 27.56
Resistance 1 27.43
Pivot 27.27
Support 1 27.07
Support 2 26.94
ETR Germany Most Active Stocks
DBK 16.49 -2.14%
DBK 16.49 -2.14%
CBK 9.38 -1.57%
CBK 9.38 -1.57%
EOAN 7.54 -1.05%
EOAN 7.54 -1.05%
DTE 17.91 0.34%
DTE 17.91 0.34%
DTE 17.91 0.34%
DTE 17.91 0.34%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
5M71 39.00 13.70%
ITN 0.32 10.34%
ZSB 0.11 10.00%
HEZ 1.03 9.57%
M6YA 0.94 9.30%
NN6 1.98 7.61%
SIS 12.13 6.97%
SIS 12.13 6.97%
SIS 12.13 6.97%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
Z1L 4.83 -90.09%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
EMQ 0.03 -25.00%
FAC 0.24 -14.29%
FAC 0.24 -14.29%
FAC 0.24 -14.29%
More..

Biotest AG (ETR: BIO)

BIO Technical Analysis 5
As on 26th May 2017 BIO Share Price closed @ 27.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 18.88 & Strong Buy for SHORT-TERM with Stoploss of 25.01 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for May
1st Target up-side 29.85
2nd Target up-side 31.15
3rd Target up-side 32.45
1st Target down-side 26.15
2nd Target down-side 24.85
3rd Target down-side 23.55
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO Address
BIO
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.